Background: The use of direct oral anticoagulant (DOAC) off-label doses in atrial fibrillation
(AF) patients may result in poor clinical outcomes. However, the true prevalence remains …

Background & Aims There is controversy over whether use of non-vitamin K antagonist oral
anticoagulants (NOACs) associates with increased risk of major gastrointestinal bleeding …

Background: Current guidelines recommend using direct oral anticoagulants (DOACs) over
warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to …

Aims The aim of this study was to compare the risk of stroke or systemic embolism (SE) and
major bleeding in patients with atrial fibrillation (AF) using dabigatran, rivaroxaban, and …

Background and Purpose: The effects of direct oral anticoagulants in nonvalvular atrial
fibrillation should be assessed in actual conditions of use. France has near-universal …

Background Chronic anticoagulation is recommended in patients with hypertrophic
cardiomyopathy (HCM) and atrial fibrillation (AF). Non-vitamin K antagonist oral …

We are interested in the estimation of average treatment effects based on right‐censored
data of an observational study. We focus on causal inference of differences between t‐year …

Background and purpose Prospectively collected data comparing the safety and
effectiveness of individual non-vitamin K antagonists (NOACs) are lacking. Our objective …

Background: There is a plethora of real-world data on the safety and effectiveness of direct-
acting oral anticoagulants (DOACs); however, study heterogeneity has contributed to …

Abstract Background Direct oral anticoagulants (DOACs) reduce the risk of stroke and
systemic embolism in patients with nonvalvular atrial fibrillation but may result in serious …